Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | MIF | P14174 | 9/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CASP3 | P42574 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.68 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15153677 | 1.00 | MAOB (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL29546087 | 1.00 | MAOB (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL980327 | 1.00 | MAOB (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL29546151 | 1.00 | MAOB (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL29679848 | 1.00 | MAOB (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL6958006 | 0.90 | MIF (1.00) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL13203410 | 0.90 | MAOB (0.81) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL14033869 | 0.90 | MAOB (0.81) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL8548101 | 0.87 | MAOB (0.77) | MAOBMIFMAPTCYP19A1PKM | |
| SCHEMBL6825622 | 0.87 | CYP19A1 (1.00) | MAOBMIFMAPTCYP19A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661407-B2 | Process for the preparation of pyrylium salts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2023-05-30 | — | — | US | disclosed |
| CN-112694449-B | Asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone catalyzed by nonmetal catalyst | 中国科学院化学研究所 | 2022-05-24 | — | — | CN | disclosed |
| CN-112694449-A | Novel nonmetal catalyst for catalyzing asymmetric hydrogenation of ketone and alpha, beta-unsaturated ketone | 中国科学院化学研究所 | 2021-04-23 | — | — | CN | disclosed |
| US-20210087158-A1 | A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-03-25 | — | — | US | disclosed |
| US-RE48156-E1 | Electronic device comprising an organic semiconducting material | NOVALED GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-10629822-B2 | Organic electroluminescent material and organic optoelectronic device | Shanghai Tianma AM-OLED Co., Ltd. (CN) | 2020-04-21 | — | — | US | disclosed |
| US-20180105477-A1 | A METHOD FOR PREPARING OPTICALLY ACTIVE CARBONYL COMPOUND | ZHEJIANG NHU COMPANY LTD. (CN) | 2018-04-19 | — | — | US | disclosed |
| US-20170256723-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170256723-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-9722183-B2 | Display | NOVALED GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010140636-A1 | ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-29 | — | — | US | disclosed |
| WO-2010066450-A1 | A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS | THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | MAOB 1483/4885MIF 1431/4885MAPT 2035/4885 |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | MAOB 2526/4885MIF 332/4885MAPT 1274/4885 |
| US-20210087158-A1 | A PROCESS FOR THE PREPARATION OF PYRYLIUM SALTS | IPO5, SF3B5, CYP4F11 | MAOB 2307/4885MIF 895/4885MAPT 2365/4885 |
| US-20100190836-A1 | Compounds, Screens, and Methods of Treatment | NLN, HTRA2, CLN6 | MAOB 874/4885MIF 2498/4885MAPT 233/4885 |
| US-10629822-B2 | Organic electroluminescent material and organic optoelectronic device | OR10J3, RPS10, H1-10 | MAOB 1215/4885MIF 771/4885MAPT 4084/4885 |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | MAOB 307/4885MIF 295/4885MAPT 4868/4885 |
| US-20180105477-A1 | A METHOD FOR PREPARING OPTICALLY ACTIVE CARBONYL COMPOUND | TPSD1, QDPR, TALDO1 | MAOB 19/4885MIF 2335/4885MAPT 573/4885 |
| US-11661407-B2 | Process for the preparation of pyrylium salts | SF3B5, IPO5, CYP4F11 | MAOB 2613/4885MIF 1345/4885MAPT 2455/4885 |
| US-20170256723-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC OPTOELECTRONIC DEVICE | OR10J3, OR51E2, RPS10 | MAOB 1216/4885MIF 882/4885MAPT 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.